Abstract 603
Background
Observational studies show that Alzheimer’s disease (AD) and lung cancer is negatively associated in both directions. However, whether there is a causal relationship between AD and lung cancer remains uncertain. Mendelian Randomization (MR) is a novel approach for the assessment of causality, using genome-wide significant single-nucleotide polymorphisms (SNP) as instrument variables (IV) to eliminate the bias caused by confounders. In this study, we utilized a bi-directional two-sample MR analysis to estimate the potential causality between AD and lung cancer.
Methods
The genome-wide association study (GWAS) summary data of AD and lung cancer were derived from the International Genomics of Alzheimer’s Project (IGAP,17,008 AD cases and 37,154 controls) and the International Lung Cancer Consortium (ILCCO, 11,348 lung cancer cases and 15,861 controls), respectively. We performed a bi-directional two-sample MR analysis to determine the causal relationship between AD and lung cancer. To be specific, Inverse-Variance Weighted (IVW), MR-Egger and Weighted Median methods were utilized for deriving causal estimates. Single SNP analysis and leave-one-out analysis were also conducted to identify if a single SNP is driving the association. We also performed the MR-Egger regression and MR-PRESSO analysis for the evaluation of horizontal pleiotropy.
Results
There was no causal relationship between AD and lung cancer in bi-directional MR. The results of Single SNP analysis and leave-one-out analysis indicated that no single SNP was driving the association. No directional horizontal pleiotropy was detected in the MR-Egger regression analysis. The MR-PRESSO analysis did not detect horizontal pleiotropy. There was no evidence for violations of MR assumptions in the sensitivity analysis.Table:
1847P Mendelian randomization estimates of the causality
Exposure | Outcome | Inverse Variance Weighted | MR Egger | Weighted Median | |||
---|---|---|---|---|---|---|---|
OR (95%CI) | P-value | OR (95%CI) | P-value | OR (95%CI) | P-value | ||
Alzheimer’s Disease | Lung Cancer | 1.040 (0.965-1.121) | 0.299 | 1.033 (0.890-1.199) | 0.676 | 0.999 (0.902-1.106) | 0.980 |
Lung Cancer | Alzheimer’s Disease | 0.919 (0.794-1.062) | 0.253 | 1.223 (0.597-2.504) | 0.637 | 0.920 (0.836-1.013) | 0.091 |
Conclusions
We found no causality between AD and lung cancer through the two-sample MR analysis. However, further study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract